Today is a very proud day for all of us. We can’t thank the amazing team at Vancouver General Hospital enough for their willingness to champion innovation and change. The results of this project mark a global first for photodisinfection as a non-antibiotic approach to reducing surgical site infections.
We have a very busy week ahead of us, so please stay tuned to this blog as we’ll be bringing you a lot more updates over the next few days.
Our MRSAid™ Photodisinfection procedure has been well received at VGH and represents a promising approach to improve patient safety in other healthcare facility settings… Photodisinfection (is) ideal for hospital settings as it eliminates the need for patient compliance as it can be administered just prior to surgery- Carolyn Cross, Chairman and CEO of Ondine.
Less than a year ago, Vancouver General Hospital implemented the MRSAid™ Photodisinfection System as part of a year-long infection control Quality Improvement Project. Since then, we are very pleased to announce that we have treated over 2,500 patients, making this one of the largest PDT studies in the world. The project is being undertaken with the objective of reducing the incidence of surgical site infections in selected surgical populations.
Many people do not know that the nose is the primary site for bacteria colonization. The average person touches their nose more than 100 times a day, and if they touch their nose and then touch their surgical site, they are at risk of giving themselves an infection that was completely preventable. Many studies have demonstrated a significant reduction in surgical site infections after nasal decolonization of both Staph and MRSA. It is therefore critical to continue the development of non-antibiotic treatments that eliminate potentially deadly bacteria from the nose.
Every year on April 7th, we celebrate World Health Day to mark the founding of the World Health Organization (WHO). Under this year’s theme of “Combating Drug Resistance,” the WHO is challenging healthcare professionals around the world to take action and implement change to address the growing problem of antibiotic resistance. Ondine is pleased to be able to respond to this challenge by entering into an innovative partnership with one of Canada’s largest hospital to introduce a novel non-antibiotic decolonization therapy aimed at reducing hospital-acquired infections (HAI’s).